| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Rubusoside does not have a specific pharmacological target but exerts its effects through multiple mechanisms. As a sweetener, it activates sweet taste receptors on the tongue. Its antiangiogenic effects are mediated through inhibition of vascular endothelial growth factor (VEGF) signaling. Its anti-inflammatory effects are associated with reduced inflammatory cell infiltration and cytokine production in airway inflammation models. As a solubilizing agent, rubusoside forms micelles that enhance the aqueous solubility of hydrophobic compounds.
|
|---|---|
| ln Vitro |
In vitro, rubusoside exhibits antiangiogenic activity by inhibiting VEGF-induced endothelial cell proliferation and tube formation. It also shows anticancer activity by inhibiting cancer cell proliferation. Rubusoside's anti-inflammatory effects have been demonstrated in cell-based assays measuring cytokine production. Its ability to enhance the solubility of hydrophobic compounds has been confirmed in various formulation studies. As a sweetener, rubusoside is approximately 100-200 times sweeter than sucrose.
|
| ln Vivo |
In vivo, rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF) in OVA-induced airway inflammation models. It has been studied for its anti-obesity and anti-allergic effects. However, specific in vivo efficacy data in animal models are not extensively detailed in the available literature. The compound is primarily used as a sweetener and solubilizing agent in food and pharmaceutical applications.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typical for rubusoside because it acts through multiple mechanisms rather than a single enzyme or receptor. However, its sweet taste receptor activation can be assessed using cell-based assays measuring calcium mobilization in sweet taste receptor-expressing cells. Its antiangiogenic activity can be assessed using endothelial cell proliferation and tube formation assays.
|
| Cell Assay |
In vitro cellular assays for rubusoside are performed using endothelial cells for antiangiogenic studies, cancer cells for anticancer studies, and immune cells for anti-inflammatory studies. Cells are treated with varying concentrations of rubusoside, and cell proliferation is measured using MTT assays. Tube formation is assessed in Matrigel-based assays. Cytokine production is measured by ELISA. Cell viability is evaluated using standard assays.
|
| Animal Protocol |
In vivo animal experiments for rubusoside are conducted in rodent models of airway inflammation, such as OVA-induced asthma models. Mice are sensitized and challenged with OVA, and rubusoside is administered orally or via inhalation. Airway hyperresponsiveness is measured using whole-body plethysmography. Inflammatory cells in bronchoalveolar lavage fluid (BALF) are counted, and cytokine levels are measured by ELISA. However, detailed protocols are not extensively documented in the available literature.
|
| ADME/Pharmacokinetics |
Rubusoside has a molecular weight of 642.73 g/mol and a molecular formula of C32H50O13. It is a natural diterpene glycoside that functions as a sweetener and solubilizing agent. The compound should be stored as a powder at -20°C for up to 3 years. Detailed pharmacokinetic parameters such as half-life, Cmax, and bioavailability have not been extensively reported. As a natural product, rubusoside is generally considered safe for consumption.
|
| Toxicity/Toxicokinetics |
The toxicological profile of rubusoside has not been extensively characterized, but it is generally recognized as safe (GRAS) as a sweetener. No significant toxicity has been reported at the concentrations used in food and pharmaceutical applications. The compound is considered safe for research use. However, comprehensive toxicology studies would be necessary for therapeutic applications.
|
| References |
|
| Additional Infomation |
Rubusoside glycoside is a steviol glycoside formed when the carboxyl and tert-allyl hydroxyl groups of steviol are converted to their corresponding β-D-glucosides. It is a valuable bioactive natural sweetener, primarily found in the Chinese sweet tea plant Rubus suavissimus. Rubusoside glycoside is both a sweetener and a plant metabolite. It is a β-D-glucoside, a tetracyclic diterpenoid, a bridging compound, and a steviol glycoside. Its function is related to steviol. Rubusoside glycoside has been reported to exist in the Chinese sweet tea plant Rubus chingii var. suavissimus, and relevant data have been reported.
Rubusoside is a natural diterpene glycoside that functions as a sweetener and solubilizing agent. It is also known as the sweet component of the Chinese sweet tea plant Rubus suavissimus. Rubusoside exhibits antiangiogenic, anticancer, anti-obesity, anti-allergic, and anti-asthmatic effects. It attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid. Rubusoside is a research compound with potential applications in inflammation, allergy, and metabolic studies. |
| Molecular Formula |
C32H50O13
|
|---|---|
| Molecular Weight |
642.7316
|
| Exact Mass |
642.325
|
| Elemental Analysis |
C, 59.80; H, 7.84; O, 32.36
|
| CAS # |
64849-39-4
|
| PubChem CID |
24721373
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
802.5±65.0 °C at 760 mmHg
|
| Flash Point |
251.9±27.8 °C
|
| Vapour Pressure |
0.0±6.4 mmHg at 25°C
|
| Index of Refraction |
1.628
|
| LogP |
1.83
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
45
|
| Complexity |
1150
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
O([C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])C12C(=C([H])[H])C([H])([H])[C@@]3(C([H])([H])C([H])([H])[C@]4([H])[C@@](C(=O)O[C@@]5([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O5)O[H])O[H])O[H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])[C@@]4(C([H])([H])[H])[C@]3([H])C([H])([H])C1([H])[H])C2([H])[H]
|
| InChi Key |
YWPVROCHNBYFTP-OSHKXICASA-N
|
| InChi Code |
InChI=1S/C32H50O13/c1-15-11-31-9-5-18-29(2,7-4-8-30(18,3)28(41)44-26-24(39)22(37)20(35)16(12-33)42-26)19(31)6-10-32(15,14-31)45-27-25(40)23(38)21(36)17(13-34)43-27/h16-27,33-40H,1,4-14H2,2-3H3/t16-,17-,18+,19+,20-,21-,22+,23+,24-,25-,26+,27+,29-,30-,31-,32+/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1R,4S,5R,9S,10R,13S)-5,9-dimethyl-14-methylidene-13-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate
|
| Synonyms |
UNII-TCV5K3M3GX; Rubusoside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~110 mg/mL (~171.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (4.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (4.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.75 mg/mL (4.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5559 mL | 7.7793 mL | 15.5586 mL | |
| 5 mM | 0.3112 mL | 1.5559 mL | 3.1117 mL | |
| 10 mM | 0.1556 mL | 0.7779 mL | 1.5559 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
